PLZF-RAR α , NPM1-RAR α , and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

• Published in: Cancers 2020-05, Vol.12 (5), p.1313
• Main Authors: Sobas, Marta, Talarn-Forcadell, Maria Carme, Martínez-Cuadrón, David, Escoda, Lourdes, García-Pérez, María J, Mariz, Jose, Mela-Osorio, María J, Fernández, Isolda, Alonso-Domínguez, Juan M, Cornago-Navascués, Javier, Rodríguez-Macias, Gabriela, Amutio, María E, Rodríguez-Medina, Carlos, Esteve, Jordi, Sokół, Agnieszka, Murciano-Carrillo, Thais, Calasanz, María J, Barrios, Manuel, Barragán, Eva, Sanz, Miguel A, Montesinos, Pau
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12051313

It has been suggested that 1-2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RAR being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RAR and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Of 2895 patients with genetically confirmed APL in the PETHEMA registry, 11 had variant APL (0.4%) (9 PLZF-RAR and 2 NPM1-RAR ), 9 were men, with median age of 44.6 years (3 months to 76 years), median leucocytes (WBC) 16.8 × 10 /L, and frequent coagulopathy. Eight patients were treated with ATRA plus chemotherapy-based regimens, and 3 with chemotherapy-based. As compared to previous reports, complete remission and survival was slightly better in our cohort, with 73% complete remission (CR) and 73% survival despite a high relapse rate (43%). After analyzing our series and performing a comprehensive and critical review of the literature, strong recommendations on appropriate management of variant APL are not possible due to the low number and heterogeneity of patients reported so far.